Overview

The severity of chronic hepatitis B (CHB) and the onset of cirrhosis and its complications are precipitated by the persistence of B viral multiplication, which generates necrotic-inflammatory activity. Thus, patient prognosis and therapeutic decisions in HCB depend on the extent of hepatic histological changes. The main aim of antiviral treatment in HCB is to suppress viral replication and maintain it over the long term. Controlling viral B replication reduces necrotic-inflammatory activity, with fibrosis improving or even regressing, even at advanced stages. The advent of antiviral agents has revolutionized the management of HCB, providing long-lasting viral suppression with the possibility of regression of the degree of fibrosis, which seems to be influenced by other factors.

Full Product Details

9786209198564

Table of Contents

Reviews

Author Information

Tab Content 6

Countries Available